We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 65.61-0.5%Jun 14 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire5/12/2006 9:05:12 PM
   of 347
MO Rep. Mott Oxford Congratulates GenoMed on Reversing Kidney Failure
ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health(TM), announced today that Missouri State Representative Jeanette Mott Oxford has offered her congratulations to GenoMed on its novel treatment for chronic kidney failure.

GenoMed was the first to prove that chronic kidney failure may not be so chronic after all, at least early in its course. GenoMed's CEO, David Moskowitz MD, showed that chronic kidney failure due to diabetes or high blood pressure can actually be reversed early in the course of the disease.

Said the Honorable Ms. Mott Oxford, Representative for Missouri's 59th House District, 'Prevention of dialysis will save federal dollars and allow a much better quality of life for Missourians. The State of Missouri will benefit from healthier, more productive people who can continue to help others, rather than be a burden themselves.'

Rep. Mott Oxford continued, 'I am particularly excited by the implication this has for our state Medicaid budget. If kidney disease from diabetes and high blood pressure can be controlled, then maybe heart disease and other complications can be, too. If so, the cost of cardiovascular disease could finally be reduced in Missouri.'

Rep. Mott Oxford added, 'Dr. Moskowitz came to my attention a few years ago when he fought for a friend of mine with emphysema to receive proper treatment in a system that wanted to deny him needed medicines. As time has passed, my admiration has only grown.'

Dr. Moskowitz was recently presented with the 2006 Defender of Patient Safety Award (physician category) by Missouri Watch ( ). His results were published in Diabetes Technology and Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied nationally, Dr. Moskowitz's method could prevent up to 90% of dialysis, and save Medicare over $22 billion a year. GenoMed owns the patents pending for this novel treatment approach
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext